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1 
INTRODUCTION 
 Institution of intra-venous thrombolysis as treatment modality for acute 
ischemic stroke has revolutionalised the field of Neuromedicine in the past few 
years. The concept of   thrombolysis and various endovascular interventions for 
acute stroke has opened the doors of the field of Interventional Neurology. The 
better availability of Neuro-imaging services has enhanced the decision making 
capacity for using acute thrombolysis. 
 Like myocardial infarction, acute ischemic stroke is equivalent to “Brain 
Attack”. It should be treated as acute emergency and top priority to be given 
during triage. Preventing the rapid loss of neurons due to ischemic insult, and 
preserving the ischemic penumbra from permanent damage is the corner stone of 
the thrombolytic therapy in AIS.  Effective treatment with proper response is 
very important in prevention of complications and improving the quality of life 
of the patient. 
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AIMS AND OBJECTIVES 
AIM OF THE STUDY  
 The aim of present study is to assess the clinical outcome and 
improvement in quality of life of patients undergoing intravenous thrombolysis 
for acute ischemic stroke in tertiary care center 
PRIMARY OBJECTIVES  
 To study the clinical profile of patients undergoing thrombolysis for acute 
stroke presenting within window period (4.5hrs) 
 To determine the age distribution of patients undergoing IV thrombolysis 
for acute ischemic stroke. 
  To study the gender distrbution among the subjects. 
 To determine the percentage of pateints presenting within the window 
period of 3 hrs and 3-4.5 hrs. 
  Risk factor assessment in patients undergoing thrombolysis. 
 To determine the percentage of patients presenting with high BP at the 
time of admission. 
 To determine the percentage of patients who needs IV anti-hypertensive 
drugs before thrombolysis therapy. 
3 
 To determine the percentage of patients who present with high blood 
glucose level at the time of admission, and determinethe mean blood 
glucse level. 
 To determine the mean NIHSS(National Institute of Health Stroke Scale) 
at the time of admission and after 24 hours. 
 To determine the percentage of people with normal CT and early 
ischemic changes in CT at the time of admission. 
 To find the mean ASPECT SCORE. 
 To determine the percentage of patients having an ischemic change or 
hemorrhagic  manifestation in CT taken 24 hours later. 
  To determine the presence of Primary outcome (reduction in NIHSS by ≥ 
4 points). 
 To study the distribution of complications. 
 To study the secondary outcome-Modified Rankin Score (mRS)  of 0-2 at 
the end of 3 months after thrombolysis to assess the quality of life.                                                         
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REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
 Stroke is an ancient disease. Imhotep, Father of Egyptian medicine, 
described stroke around 3000 BC
1,2
. In 1600 Thomas Willis described Circle of 
Willis and used the term “Apoplexy”. Modern era of stroke started when Miller 
Fisher described stroke and its features. In the last few years there was a 
tremendous change in management of stroke. Introduction of IV rt-PA in 1996 
as proven effective treatment was a trend setter in the field of medicine. The 
dawn of the field of interventional neurology by using endovascular therapies is 
another milestone in treatment of stroke in recent time. An improvement in 
neuroimaging and diagnostic services is also of paramount importance in the 
development of field of neuromedicine. 
 TIME IS BRAIN 
 The average number of neurons in human cerebrum is 22 billion. When 
there is an ischemia, in a minute about 1.9 million neurons, 14 billion synapses, 
and 12 km length of myelinated fibers are lost
3
.  With passing of each hour the 
ischemic brain ages 3.6 years more than normal. Prompt intervention is very 
essential for maintaining the neuronal cell mass by protecting them from the 
ischemic insult. 
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BLOOD SUPPLY OF BRAIN
4
 
 The entire blood supply of the brain and spinal cord depends on two sets 
of branches from the dorsal aorta. The vertebral arteries arise from the sub-
clavian arteries, and the internal carotid arteries are branches of the common 
carotid arteries. The internal carotid arteries branch to form two major cerebral 
arteries, the anterior and middle cerebral arteries. The right and left vertebral 
arteries come together at the level of the pons on the ventral surface of 
the brainstem to form the midline basilar artery. The basilar artery joins the 
blood supply from the internal carotids in an arterial ring at the base of the brain 
called the circle of Willis. The posterior cerebral arteries arise at this confluence, 
as do two small bridging arteries, the anterior and posterior communicating 
arteries. Conjoining the two major sources of cerebral vascular supply via the 
circle of Willis presumably improves the chances of any region of the brain 
continuing to receive blood if one of the major arteries becomes occluded. 
 
Figure-1 Blood supply of brain- The Circle of Willis. 
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CLASSIFICATION OF ISCHEMIC STROKE (TOAST CRITERIA)
5,6
: 
 Large artery atherosclerosis. 
 Cardio embolic stroke. 
 Small vessel occlusion (lacunar). 
 Stroke of undetermined origin. 
ISCHEMIC PENUMBRA  
 The concept of ischemic penumbra
7 
explains the capacity of hypo-
perfused neurons to recover when the perfusion is improved. Hypo-perfusion is 
not enough to cause permanent damage. The area of ischemic penumbraregains 
function if the occluded vessels are re-canalized. Ischemic penumbra is a 
dynamic process, present even in the core of infarct for a short period of time 
before irreversible damage sets in (figure -2). Earlier the treatment salvage of 
more neural tissue is possible.  
 The main aim of thrombolysis is to salvage maximum number of neurons 
in the penumbra by earlier restoration of blood flow to the ischemic tissue and 
also minimizing the tissue reperfusion injury (figure -3). 
 
Figure-2 Concept of ischemic penumbra 
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Figure-2 Concept of ischemic penumbra. 
PREHOSPITAL MANAGEMENT 
PUBLIC EDUCATION  
 The good functional outcome of early stroke management begins with 
recognition of stroke when it occurs. Many studies demonstrate that public 
education
8 
about signs and symptoms of stroke improves recognition. The targets 
should be prospective patients, their family members and caregivers empowering 
them to call emergency services promptly. The FAST algorithm
9 
(face, arm, 
speech, time) is the most commonly used message for campaign (figure-3). 
“ACT FAST” is the slogan used to educate emergency services and general 
public to know the benefits of reaching medical services earlier for better 
outcome. Distribution of flyers, posting banners at prominent places of public 
gatherings and conduction of classes comprise of methods of spreading the 
information. Introduction of the concept among school and college going 
youngsters may be useful method of educating large number of people at a same 
time
10,11
. 
8 
 
Figure-4 ACT FAST algorithm. 
STROKE CHAIN OF SURVIVAL 
Detection- by patient or bystander 
Dispatch- calling emergency services 
Delivery- prompt transport to appropriate Centre 
Door to emergency triage 
Data- prompt evaluation, laboratory studies and imaging 
Decision –diagnosis and appropriate treatment 
Drug administration or other interventions 
Disposition- timely admission in intensive care unit 
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STROKE SYSTEMS OF CARE 
 Stroke systems of care integrate regional stroke facilities and acute 
stroke-ready hospitals with primary and comprehensive stroke centers. The goals 
of creating stroke systems of care include stroke prevention, community stroke 
education, proper use of emergency services, effective acute stroke care, and 
rehabilitation. 
PRIMARY STROKE CENTER (PSC): 
PSC improves stroke care in many ways (i.e.) by  
 Shortening door to physician Contact time  
 Door to CT time 
 Door to intravenous rt-PA time  
 Increasing rates of intravenous rt-PA use 
COMPREHENSIVE STROKE CENTER (CSC): 
 CSC should be able to offer 24 hours per day, 7 days per week with state 
of the art care on the full spectrum of cerebrovascular diseases. In patients with 
acute ischemic stroke, admission to Neuro-Intensive Care units are done for 
those 
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 With severe deficits 
 Large-volume infarcts  
 Significant cerebral edema  
 Significant comorbidities 
 Blood pressure that is difficult to control 
 Prior intravenous and intra-arterial recanalization interventions 
ACUTE STROKE-READY HOSPITAL (ASRH) 
 ASRH are hospitals that effectively and efficiently evaluate, diagnose, 
and treat most stroke patients but they do not have inpatient stroke systems of 
care. After initial evaluation and treatment the patients are shifted to 
comprehensive stroke centers for overall care. 
 All ASRH have the following facilities 
•  Written emergency stroke care protocols 
•  Written transfer agreement with a hospital with neurosurgical expertise 
•  Ability to administer intravenous rt-PA 
•  Ability to perform emergency brain imaging. 
• Ability to conduct emergency laboratory testing 
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TELEMEDICINE OR “TELESTROKE”12 
 Telemedicine (also called telestroke) help to solve the shortage of 
neurologists and radiologists, allowing hospitals to become acute stroke ready. 
Telemedicine provide acute stroke expertise to hospitals without full-time 
neurological services Tele stroke networks are reasonable for triaging patients 
with AIS who may be eligible for inter-facility transfer in order to be considered 
for acute interventions 
TELE-RADIOLOGY 
 Tele-radiology is useful to obtain radiographic images at one location and 
transmit them to another for diagnostic and consultative purposes. Images can be 
transferred through internet or using smartphones
13 
to the radiologist to obtain 
the diagnosis.  
EVALUATION AND DIAGNOSIS OF STROKE 
 Patient suspected with acute stroke should be triaged
14
 with same priority 
as that of myocardial infarction or trauma. Initial evaluation of stroke patient 
includes immediate stabilization of airway breathing and circulation as in other 
emergency patients. 
TIMELINE FOR MANAGEMENT
15
 
 Door to physician ≤10 minutes 
 Door to stroke team ≤15 minutes 
12 
 Door to CT initiation ≤25 minutes 
 Door to CT interpretation ≤45 minutes 
 Door to drug (≥80% compliance) ≤60 minutes 
 Door to stroke unit admission ≤3 hours 
PATIENT HISTORY 
 Important information to be obtained is the time of onset of stroke. The 
time last when the patient was symptom free is asked for. The events occurring 
along with the occurrence of stroke should also be recorded. Wake up stroke can 
also be treated with thrombolysis if the imaging studies favor acute stroke with 
normal or early CT changes and fulfills the requisites for acute intervention.  
CLINICAL SITUATIONS THAT MIMIC STROKE 
 Psychogenic 
 Seizures 
 Hypoglycemia 
 Migraine with aura 
 Hypertensive encephalopathy 
 Wernicke’s encephalopathy 
 CNS abscess  
13 
 CNS tumor 
 Drug toxicity-lithium, phenytoin, carbamazepine 
STROKE SCALES
16
 
 The use of a standardized neurological examination ensures that the 
components of a neurological examination are performed in a timely and 
uniform fashion. Formal stroke scores or scales, such as the NIHSS or Canadian 
Neurological Scale, may be administered by a broad spectrum of healthcare 
providers. 
NATIONAL INSTITUTES OF HEALTH STROKE SCALE 
 The NIHSS
17,18
 is an 11 item impairment scale, which provides a 
quantitative measure of key components of a standard neurological examination 
The score assesses the following parameters 
1. Level of consciousness 
2. Best gaze 
3. Visual fields 
4. Facial paresis 
5. Motor-arm 
6. Motor-leg 
14 
7. Limb ataxia 
8. Sensory 
9. Best language 
10. Dysarthria 
11. Extinction or inattention 
 Each of the 11 items scores a specific ability between 0-4. Score 0 
indicates normal function and higher score is indicative of impairment. 
Individual scores are summed up to get the final score. Scoring sheet is attached 
in annexure. 
 The minimum score is 0 and maximum score is 42. Severity of the stroke 
can also be assessed using NIHSS score (table-1). 
Table - 1 
Score severity 
0 No stroke symptoms 
1-4 Minor stroke 
5-15 Moderate stroke 
16-20 Moderate to severe stroke 
21-42 Severe stroke 
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1. LEVEL OF CONSCIOUSNESS: 
 Level of consciousness testing is in three sub- sections. The first section 
tests for the patient's responsiveness. The second section is the patient's ability to 
answer questions that are verbally asked by the examiner. The third section is 
based on the patient's ability to follow commands to perform some simple task. 
The scores are consolidated and represented in as a single component. 
1.A. LOC RESPONSIVENESS 
Table - 2 
Score Test results 
0 Alert, responsive 
1 Not alert, arousable verbally or by minor stimulation 
2 Not alert, responsive to repeated  and strong stimuli 
3 Totally unresponsive , responds only with reflexes or areflexic 
 
1.B.  LOC QUESTIONS: 
 Patient is asked for his or her age and the current month of the year 
16 
Table - 3 
Score Test results 
0 Answers both questions correctly 
1 Answers one question  
2 Does not answer both questions correctly 
 
1.C. LOC COMMANDS 
 Patient is asked to do two commands, to open and close the eyes and to 
grip the hands. Commands can be repeated once only. Results are interpreted 
Table - 4 
Score Test results 
0 Can perform two commands. 
1 Can perform one command. 
2 Can’t perform both the commands. 
 
2.  BEST GAZE 
 Assess the ability to follow an object or pen 
Table - 5 
Score Test results 
0 Able to follow pen fully 
1 Partial gaze palsy 
2 Total gaze palsy, fixed  to the side of  lesion 
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3. VISUAL FIELD TEST 
 Visual fields tested by confrontation method and results are interpreted. 
Each eye is tested individually. 
Table - 6 
Score Test results 
0 No vision loss 
1 Partial hemianopia or complete quadrantanopia 
2 Complete hemianopia 
3 Bilateral blindness 
 
4. FACIAL PALSY 
 The movements of the facial expression are tested for partial or complete 
paralysis. UMN type of facial palsy is assessed. Symmetry of the face is noted in 
each facial expression. 
Table - 7 
Score Test result 
0 Normal and symmetrical 
1 Minor paralysis 
2 Partial paralysis 
3 Complete facial paralysis 
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5.  MOTOR ARM 
 The pronator drift test is performed in each upper limb. The patient is 
asked to extend his or her arm 90 degree out in the front. Observe for any 
downward drift of the arm within 10 seconds. Each arm should be tested 
individually for power. A maximum score of 4 for each arm totaling to 8 is 
interpreted. 
Table - 8 
Score Test results 
0 No arm drift 
1 Arm drifts to intermediate position 
2 Limited effort against gravity 
3 No effort against gravity 
4 No movement 
 
6. MOTOR LEG 
 The patient is tested in supine position. One leg is lifted 30 degree above 
the horizontal and drift of the limb downwards in less than 5 seconds. Here also 
the score for individual legs are 4 totaling to 8. 
 
 
 
19 
Table – 9 
Score Test results 
0 No leg drift 
1 Drifts to intermediate position in 5 seconds 
2 Limited efforts against gravity 
3 No effort against gravity 
4 No movement 
 
7.  LIMB ATAXIA 
 This is to test the intactness of the cerebellum. Finger Nose Test and Heel 
Knee Test are conducted. Both sides are tested separately. Patient’s eye should 
be open when testing. 
Table - 10 
Score Test result 
0 Normal ,smooth, and coordinated movements 
1 Ataxia in one limb 
2 Ataxia in both the limbs 
 
8.  SENSORY 
 Tested using pin pricks. Individual dermatomes are tested and results are 
interpreted. 
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Table - 11 
Score Test results 
0 No sensory deficit 
1 Mild to moderate deficit 
2 Severe deficit  
 
9.  LANGUAGE 
 The stroke scale includes a picture of a scenario. A list of simple 
sentences, a figure of assorted. Then the patient has to read the list of sentences 
and name the objects  
Table - 12 
 
10 DYSARTHRIA 
 Dysarthria is the lack of motor skills required to produce understandable 
speech. It is the motor component of speech which is tested. The patient is asked 
to read out the list of words provided with the scale. Examiner observes the 
clarity and articulation of the words. 
Score Test results 
0 Normal  
1 Mild to moderate aphasia 
2 Severe aphasia, fragmented speech 
3 Unable to speak or understand the speech 
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Table - 13 
Score Test result 
0 Normal speech 
1 Mild to moderate dysarthria 
2 Severe dysarthria  
 
11. EXTINCTION AND INATTENTION 
 This is tested by a technique referred as double simultaneous stimulation. 
Here the examiner alternatingly touches on right and left sides of the patient in 
various spots. Visual, tactile, auditory and spatial orientation is tested. The 
results are interpreted as 
Table - 14 
Score Test results 
0 Normal  
1 Inattention to one side or one modality 
2 Hemi-inattention no recognition of stimuli. Involvement of more than 
one modality.  
 
USAGE OF NIHSS SCORE
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  It is a standardized and repeatable assessment of stroke patients used by 
large multi-centric trials. It is the recommended scoring system by 2018 
ASA/AHA guidelines on acute ischemic stroke. NIHSS used as soon as the 
22 
patient is admitted and then is repeated at regular intervals. It can also be used to 
monitor the response of therapy 
NIHSS USE IN THROMBOLYSIS 
 A score of range 7-22 is indicated for thrombolysis. Score less than 7 
indicate minor stroke.  Hence it is not prudent to use thrombolytic since the risk 
of intracranial bleed is higher. Stroke presenting with score more than 22 are 
considered severe. Use of thrombolytic in major stroke is of minimum use since 
the area of occlusion is more involving major arteries it may not be possible to 
re-canalize the vessels fully. In addition the mortality in major strokes is high 
and general condition of the patient is also very poor.  
MODIFIED NIHSS SCORE 
 It is the shorter version of the scale available. Some of the section are 
removed so as it can be easily applied by everyone. The simplified version is of 
more useful and is recommended for use of paramedical staff in assessing the 
patients prior to admission in hospital. 
DRAWBACKS OF NIHSS 
 The score does not evaluate cranial nerves in detail. So it may be difficult 
to assess them separately while assessing the patient for thrombolysis. The score 
is also poor in assessing brainstem and cerebellar infarctions. Score may be low 
even in disabling strokes in these regions. 
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OTHER SROKE SCALES AVAILABLE 
 Canadian Neurological Scale 
 Scandinavian Stroke Scale 
 Orogogozo Scale 
 mTICI score 
 Modified Mathew Scale 
INITIAL DIAGNOSTIC EVALUATION OF PATIENTS WITH ACUTE 
STORKE 
 Several tests to assess for serious comorbid disease aid in treatment 
selection. Search for acute medical or neurological complications of stroke 
should be routinely emergently performed in all patients with suspected ischemic 
stroke. These are primarily to exclude important differential diagnosis. 
  The latest recommendations as per 2018 ASA/AHA guidelines are as 
follows 
 Only the assessment of blood glucose must precede the initiation of IV rt-
PA in all patients. 
 Baseline ECG assessment is recommended in patients presenting with 
AIS, but should not delay initiation of IV rt-PA. 
24 
 Baseline troponin assessment is recommended in patients presenting with 
AIS, but should not delay initiation of IV rt-PA 
 Usefulness of chest radiographs in the hyper acute stroke setting in the 
absence of evidence of acute pulmonary, cardiac, or pulmonary vascular 
disease is unclear. If obtained, they should not unnecessarily delay 
administration of IV rt-PA 
OTHER DIAGONSTIC EVALUATIONS TO BE DONE 
SUBSEQUENTLY IN ALL PATIENTS: 
 Oxygen saturation 
 Serum electrolytes/renal function tests 
 Complete blood count, including platelet count 
 Markers of cardiac ischemia 
 Prothrombin time(PT) / INR 
 Activated Partial Thromboplastin Time (aPTT) 
 ECG 
INVESTIGATIONS TO BE DONE IN SELECTED PATIENTS 
 TT  if the patient is taking direct thrombin inhibitors or direct factor Xa 
inhibitors 
25 
 Hepatic function tests 
 Toxicology screen 
 Blood alcohol level 
 Pregnancy test 
 Arterial blood gas tests (if hypoxia is suspected) 
 Chest radiography (if lung disease is suspected) 
 Lumbar puncture (if subarachnoid hemorrhage is suspected and CT scan 
is not showing evidence of bleeding). 
 Electroencephalogram (if seizures are suspected) 
NEUROIMAGING 
 Neuro imaging
19
 plays an important role in management of AIS. CT and 
MRI form the backbone of clinical assessment of acute ischemic stroke. There 
are many other clinical conditions that may mimic AIS. They are intracranial 
hemorrhage, seizure, sepsis, cardiogenic syncope, migraine, dementia, non-
ischemic spinal cord pathologies, peripheral neuropathy, transient global 
amnesia, and brain abscess or tumor.  
 Modern imaging techniques are useful in establishing the diagnosis with a 
high degree of certainty  in the very rapid time. 
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NON-CONTRAST CT (NCCT)
20
 
 The primary purpose of NCCT in the acute stroke setting is to diagnose 
ischemic stroke, and to exclude acute intracranial hemorrhage. Frank ischemia or 
hemorrhages are easily visible in NCCT. NCCT remains easiest and rapid 
method to assess the patient condition in emergency situations. Availability of 
CT centers is also widespread in our country and CT can be done within minutes 
of arriving in the emergency room. Even when the patients arrive in time if they 
intracranial hemorrhage or an evolved stroke they cannot be thrombolysed. Thus 
NCCT remains an important tool for initial evaluation
21
 of ischemic stroke.  
 
Figure - 4 Normal CT 
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Figure-5 CT with frank ischemic infarction. 
 
Figure -6 CT with intra-cerebral (A) and sub arachnoid hemorrhage(B) 
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EARLY CT CHANGES
22
 IN AIS 
 Early decreases in the CT density of ischemic tissue are appreciated only 
indirectly. The following are the early changes CT after ischemia before 
developing frank infarct. 
LOSS OF GREY-WHITE MATTER DIFFERENTIATION 
 The process of decrease in CT density initially affect gray matter more 
than white matter. Decreasing the radio density of affected gray matter slightly, 
so that it approaches that of adjacent white matter. The loss of gray matter–white 
matter differentiation is a commonly described early sign of acute infarction on 
NCCT 
OBSCURATION OF LENTIFORM NUCLEUS 
 When infarction is in the territory of the middle cerebral artery (MCA), 
this is often manifested as obscuration of the basal ganglia and the lentiform 
nucleus. 
LOSS OF SULCAL EFFACEMENT 
 Early edema is visible because the increase in volume of brain tissue. This 
causes effacement of nearby cerebral sulci, cisterns, or ventricles. Thus there is 
no normal space between the sulci and gyri. 
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INSULAR RIBBON SIGN 
 When infarction is in the territory of MCA, may present as the ‘‘Insular 
Ribbon Sign’’ in which the ribbon of gray matter in the insular cortex becomes 
indistinguishable from the subcortical white matter 
 
Figure-7 Insular Ribbon sign 
HYPERDENSE MCA SIGN
23
 
  Emboli are more radio dense than normal brain tissue. So an affected 
proximal MCA may appear as a linear hyper density in the sylvian fissure this is 
known as‘‘Hyperdense Middle Cerebral Artery sign’’ or HMCA sign. 
30 
 
Figure-8: Hyperdense MCA sign 
MCA DOT SIGN
24
 
 Hyper dense embolic material in more distal MCA branch, within the 
Sylvian fissure which is oriented in perpendicular plane of imaging may appear 
as a small, rounded hyperdensity. This is known as ‘‘MCA dot sign.’’ 
 
Figure-9:  MCA dot sign 
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THE ALBERTA STROKE PROGRAMME EARLY CT SCORES 
(ASPECTS)
25
 
 The Alberta Stroke Programme Early CT Score (ASPECTS) helps to 
improve reliability in CT reading, even among non-expert.  It provides a 
framework for quantifying the extent of ischemic hypodensity in early NCCT 
scans. In ASPECTS, each of the 10 distinct regions in the territory of the MCA 
is assigned a score of 0 or 1 depending on the presence or absence of 
hypodensity. 
 One point is subtracted from 10 for each early CT change. Thus, a score 
of 10 indicates no hypodensity 0 reflects hypodensity.  ASPECTS is helpful in 
diagnosing acute stroke, and to decide whether or not thrombolytic therapy is to 
be administered. ASPECTS scores of 7 or less indicates presence of hypodensity 
and associated with an increased risk of thrombolysis-related parenchymal 
hemorrhage. 
CONVENTIONAL MRI 
 The conventional MRI is capable of detecting early changes in neural 
tissue. Because of vasogenic edema, which introduces mobile water protons into 
ischemic tissue the ischemic region is visible as hyperdense areas due to 
increased signal intensity 
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MRI-FLAIR 
 T2-weighted fluid-attenuated inversion recovery (FLAIR) imaging 
provide increased sensitivity. It shows hyper intense lesions in the ischemic 
regions better than the conventional MRI. 
OTHER SIGNS OF ACUTE STROKE ON MRI 
 Loss of vascular flow voids 
 Arterial hyperintensity in FLAIR images 
 Vascular contrast enhancement signifying stasis of blood 
 Effacement of sulci, cisterns, and ventricles due to mild swelling. 
DIFFUSION-WEIGHTED MRI (DWI)
26
 
 A major breakthrough in stroke imaging occurred with the development 
of diffusion- weighted MRI (DWI). DWI produces images that are T2-weighted 
and diffusion-weighted. Diffusion weighted means that different parts of the 
brain appear brighter or darker depending on the rate of water diffusion within 
them.   
 Diffusion is also known as Brownian motion
27
, which is the random 
motion that all molecules exhibit when at temperatures above absolute zero. In 
brain tissue, this motion is reduced by physical barriers like cell membranes and 
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cytoskeletal macromolecules. DWI is able to depict microscopic pathologic 
changes by demonstrating changes in water diffusion
28
. 
 In ischemic brain tissue, diffusion of water molecules becomes markedly 
restricted, within minutes of the onset of ischemia, because of cytotoxic edema. 
 Cytotoxic edema is distinct from vasogenic edema, occurs due to an 
accumulation of ions in the intracellular space. This leads to cellular swelling, 
but not tissue swelling which is depicted as a hyperintense lesion in diffusion-
weighted images. 
 
Figure -10 comparison of CT, MRI and diffusion weighted image 
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MAGNETIC RESONANCE ANGIOGRAPHY 
 MRA can be divided into contrast-based techniques and non-contrast 
based techniques. 
There are two non-contrast based MRA techniques  
 Time-of-flight(TOF) MRA 
 Phase contrast (PC) MRA. 
 MRA can also be performed with intravenously injected bolus of a 
gadolinium-based contrast material 
CT ANGIOGRAPHY 
 CT angiography (CTA)
30
 is a technique that provides high-resolution 
vascular images using the same CT scanners that are used for conventional CT 
imaging. The Iodine-based contrast agents are used for conventional contrast-
enhanced CT                                         
 
 
Figure -11 CT angiography. 
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2018 AHA/ASA GUIDELINES REGARDING NEURO IMAGING FOR 
AIS 
 All patients with suspected AIS should undergo NCCT to provide 
information to make decisions on treatment modality 
 Brain imaging should be done within 20 minutes of arrival to the hospital 
in patients who are candidates for IV rt-PA. 
 Early CT changes should not be used as a criteria to withhold the therapy 
who otherwise qualify 
 Routine use of MRI before IV rt-PA administration is not recommended 
 MRI and other imaging should not delay the administration of therapy 
with IV rt-PA. 
 SUPPORTIVE CARE AND TREATMENT OF ACUTE 
COMPLICATIONS IN PATIENTS OF AIS 
AIRWAY, VENTILATORY SUPPORT 
 Assessment of the airway, breathing, and circulation occurs in the pre-
hospital and on arrival in emergency room. If the there is any problem with the 
above it should be corrected promptly. 
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HYPOXIA 
Common causes of hypoxia are 
 Partial airway obstruction, 
 Hypoventilation, 
 Aspiration,  
 Atelectasis and pneumonia 
 Impaired oropharyngeal mobility  
 Loss of protective reflexes 
 Central periodic breathing (Cheyne-Stokes respirations) 
PATIENT POSITIONING
32
 
 Non-hypoxic patients, a supine position
33,34  
is recommended. Patients at 
risk for airway obstruction or aspiration should have the head of the bed elevated 
15° to 30° 
TEMPERATURE
35,36 
 
HYPERTHERMIA 
 About one third of patients admitted with stroke will be hyperthermic 
(temperature >37.6°C) in the first one hour of onset.  Hyperthermia is associated 
with poor neurological outcome, due to increased metabolic demands, increased 
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release of neurotransmitters, and free radical production. Hyperthermia may also 
be the cause of stroke, like infective endocarditis. It may be due to a 
complication, like pneumonia, urinary tract infection or sepsis 
37
. 
HYPOTHERMIA 
 Benefits of induced hypothermia which can protect the brain in the 
presence of global hypoxia or ischemia are not established. Efforts to reduce the 
temperature are not needed. 
CARDIAC MONITORING 
 Continuous cardiac monitoring is indicated for at least the first 24 hours 
after stroke. Occurrence of atrial fibrillation and other cardiac arrhythmias is 
carefully monitored.  
ACUTE STROKE AND BLOOD PRESSURE
38
 
ARTERIAL HYPERTENSION 
 The blood pressure monitoring in patients with AIS is very essential in 
the setting of  IV thrombolysis. Generally patients presented with SBP of 
>139mmHg were 77% and >184 mmHg were 15%
38
. 
 Blood pressure reduces spontaneously starting within 90 minutes after 
onset of stroke symptoms. Extreme arterial hypertension is clearly detrimental, 
because it leads to encephalopathy, cardiac complications, and renal 
insufficiency 
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Moderate arterial hypertension during acute ischemic stroke might be 
advantageous by improving cerebral perfusion of the ischemic tissue. 
OPTIONS TO TREAT ARTERIAL HYPERTENSION IN PATIENTS 
WITH AIS  
PATIENTS ELIGIBLE FOR ACUTE REPERFUSION THERAPY AND 
BP IS >185/110 MM HG
39
 
 Labetalol 10–20 mg IV over 1–2 min, may repeat 1 time 
 Nicardipine 5 mg/h IV, increase 2.5 mg/h every 5–15 min, maximum 15 
mg/h. 
 Clevidipine 1–2 mg/h IV, double the dose every 2–5 min until desired BP 
reached; maximum 21 mg/h 
 Other agents like hydralazine, enalaprilat  may also be considered 
 If BP is not maintained ≤185/110 mm Hg, do not administer alteplase 
MANAGEMENT OF BP DURING AND AFTER ALTEPLASE IS TO 
MAINTAIN BP ≤180/105 MM HG 
 Monitor BP40 every 15 min for 2 h from the start of alteplase therapy 
 Every 30 min for 6 h 
 Every hour for 16 h 
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IF SYSTOLIC BP >180–230 MM HG OR DIASTOLIC BP >105–120 MM 
HG 
43,44,45
 
 Labetalol 10 mg IV stat followed by continuous IV infusion 2–8 mg/min.   
 Nicardipine 5 mg/h IV, dose increased up to desired effect by 2.5 mg/h 
every 5–15 min, maximum 15 mg/h 
 Clevidipine 1–2 mg/h IV, titrate by double the dose every 2–5 min until 
desired BP reached- maximum 21 mg/h 
 If BP not controlled or diastolic BP >140 mm Hg, consider IV sodium 
nitroprusside 
INTRAVENOUS FLUIDS 
 Patients presenting with acute ischemic stroke are either euvolemic or 
hypovolemic. Hypovolemia may lead to hypoperfusion and exacerbate the 
ischemic brain injury. 
 Hypervolemia  may exacerbate ischemic brain edema. Thus euvolemia is 
desirable. Appropriate IV fluids should be infused to the patient to maintain 
euvolemic status. 
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BLOOD GLUCOSE LEVELS
46
 
HYPOGLYCEMIA 
 Blood glucose should be measured in all patients with acute ischemic 
stroke. Autonomic symptom like sweating, trembling, or anxiety appear when 
the blood glucose level reduces less than 57 mg/dl. Brain dysfunctions like 
disorientation, dizziness begin to appear when the glucose level is below 47 
mg/dl. It is important to correct the levels with slow IV infusion of dextrose 
containing solutions. 
HYPERGLYCEMIA
47,48
 
 It has been shown by several studies that the admission blood glucose is 
elevated in >40% of patients with AIS. Most of the patients with hyperglycemia 
are diabetics, hence special care should be taken to reduce the blood sugar to the 
desirable levels i.e 140-180mg/dl. Short acting insulin can be used. Serial 
monitoring of blood glucose levels are desirable.   
HIGHLIGHTS OF 2018 AHA/ASA GUIDELINES REGARDING 
SUPPORTIVE CARE 
 Airway and ventilatory support is recommended for patients with 
decreased consciousness or compromised airway. 
 Oxygen supplementation  not needed in non-hypoxic patients 
 In hypoxic patients it should be given to maintain saturation >94% 
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 Euvolemic status to be maintained 
 Hyperthermia to be treated with anti-pyretics 
 No role for induced hypothermia established 
 Blood glucose levels optimally maintained between 140 and 180mg/dl 
 In patients with elevated blood pressure who are eligible for IV therapy, it 
should be carefully lowered to the levels SBP <185mmHg and DBP 
<110mmHg 
INTRAVENOUS FIBRINOLYSIS
48
 
 Intravenous fibrinolytic therapy for acute stroke is now widely accepted. 
The US FDA approved the use of intravenous rt-PA in 1996 on the basis of 
NINDS rt-PA Stroke Trial. Thrombolytic therapy with IV rt-PA is the most 
effective treatment for acute ischemic stroke. 
RATIONALE FOR THERAPY 
 The reduced cerebral blood flow due to acute arterial occlusion reduces 
oxygen and glucose supply to the brain tissue
49
. It leads to  
 Lactic acid production 
 Blood–brain barrier breakdown 
 Inflammation 
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 Sodium and calcium pump dysfunction, 
 Glutamate release and intracellular calcium influx 
 Free-radical generation 
 Membrane and nucleic acid breakdown 
 Cell death. 
  Brain tissue with cerebral blood flow <8–10 mL/100 g/min will not 
survive. While brain tissue with cerebral blood flow 18–20 mL/100 g/min makes 
the tissue nonfunctional. This tissue may recover from permanent damage if the 
blood flow is restored rapidly within the time. It is the basis of the concept of the 
ischemic penumbra surrounding a zone of irreversible damage Restoration of 
blood flow to the penumbra is the goal of thrombolytic therapy. The window 
period for treatment with IV rt-PA is < 4.5 hrs from the onset of symptoms. Late 
reperfusion may be associated with reperfusion injury and hemorrhagic 
transformation of the infarction with worser outcomes than without treatment. 
INTRAVENOUS THROMBOLYTICS 
 Thrombolytic agents
50 
are drugs which cause dissolution of thrombi. They 
act by converting inactive plasminogen into plasmin which is a serine protease. 
The plasmin then cleaves fibrin within the thrombus.  
43 
                
Figure -12 mechanism of action of thrombolysis 
 Intravenous thrombolytic agents that can be used for stroke thrombolysis 
are as follows 
 Human rt-PA(Alteplase)55 
 Tenectiplase  
 Urokinase  
 Streptokinase 
 Desmoteplase.  
 Only alteplase and tenecteplase are the two drugs which are FDA 
approved for IV thrombolysis. Other drugs are not of proven benefit in treatment 
of AIS
56
. 
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Administration of these agents cause
59
 
 systemic fibrinogen degradation 
 reduction in plasminogen and a2-antiplasmin 
 inactivation of factors V and VIII 
 platelet disaggregation and platelet dysfunction 
 systemic hypofibrinogenemia 
 prolongation of aPTT and coagulopathy. 
 
Figure- 13 Mechanism of action of IV rt-PA 
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DOSE AND ADMINISTRATION 
ALTEPLASE
59
 
 IV alteplase is given in the dose of 0.9 mg/kg maximum of 90mg 10% of 
the dose is given as bolus over 1 minute Remaining dose is given as IV infusion 
over 1 hour  
TENECTIPLASE 
IV tenectiplase can be given as a single dose.  
0.4mg/kg as IV bolus. 
Delay nasogastric tube insertion, bladder catheterization or other catheterization. 
Follow up CT or MRI at 24 hours. 
INDICATIONS
60,61
: 
 Class I recommendations- strong benefit 
 Class II recommendations- moderate or weak benefit 
CLASS I RECOMMENDATIONS: 
 Patients with acute ischemic stroke presenting within 3hrs of onset of 
symptoms 
 Age ≥18 and <80 yrs 
 Stroke severity NIHSS score <25 
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 Normal NCCT or early CT changes with ASPECT score < 6 
 In selected patients presenting between 3- 4.5 hours( < 80yrs, no prior 
diabetes or stroke, not on oral anticoagulants and without imaging 
evidence of infarct) 
 Patients on single or dual antiplatelet drugs 
 ESRD patients on HD with normal aPTT 
CLASS II RECOMMENDATIONS 
 Extended 3-4.5 hours62 for age >80 years 
 Patients on warfarin with INR <1.7 
 Within 0-3hrs window with mild stroke i.e NIHSS< 4 
 3-4.5 with severe stroke NIHSS >25 
 Pre-existing disability mRS score >2 
 Blood pressure >185/110 mmHg(to be corrected to<185/110mmHg) 
 Hypoglycemia and hyperglycemia(to be maintained between 140-
180mg/dl) 
 Seizure at onset 
 Dural or lumbar puncture in last 7days 
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 Arterial puncture in last 7 days 
 Recent major trauma within 14 days not involving head 
 Recent major surgeries within 14 days 
 Menstruation with no history of menorrhagia 
 Small <10mm unruptured intracranial aneurysms 
 Cranial microbleeds(CMB) 1-10 number on MRI  
 Extra-axial intracranial neoplasms 
 Acute MI if immediate PCA is indicated 
 Recent MI within 3 months  
 Cardiac diseases- cardiologist consultation is needed 
 Procedural stroke –during cardiac or cerebral angiography 
 Systemic malignancy with life expectation >6 months 
 Pregnancy  
 Hemorrhagic ophthalmic conditions 
 Sickle cell disease 
 Illicit drug users 
 Stroke mimics 
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CONTRAINDICATIONS (CLASS III RECOMMENDATIONS): (no 
benefit or cause harm) 
 Time of onset more than 4.5hrs 
 CT showing acute intracranial hemorrhage, acute frank infarct, ASPECT 
< 6 
63.
 
 Ischemic stroke within 3 months 
 Severe head trauma within 3 months 
 Intracranial / intraspinal surgeries within 3 months 
 Previous history of intracranial hemorrhage  
 Subarachnoid hemorrhage 
 GI bleed within 21 days  
 GI malignancy 
 Coagulopathy (platelet<1,00,000/mm3,INR >1.7, aPTT >40 sec, PT >15 
sec) 
 LMWH or unfractionated heparin in past 24 hours 
 Patients on Thrombin inhibitors or Direct Xa inhibitors 
 Patients on glycoprotein IIb/IIIa inhibitors 
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 Infective endocarditis 
 Aortic arch dissection 
 Intra-axial intracranial neoplasms 
COMPLICATIONS 
 The complication following IV alteplase infusion is relatively minimal 
but maybe life threatening. They are as follows 
 Minor skin rash 
 Anaphylactic reactions and angioedema 
 Minor intracranial bleed67 
 Major intracranial bleed67 
 Extracranial bleeding manifestation 
 Other complications                         
ANGIOEDEMA AND ANAPHYLAXIS
68
 
 Angioedema reaction comprise of swelling of tongue, lips or oropharynx. 
They are usually mild transient and occurs mostly on the opposite side of 
ischemic hemisphere. Occurs in about 1.3%-5.1% 0f all patients who receive 
alteplase. 
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MANAGEMENT
69
 
 Maintenance of airway 
 Discontinue alteplase infusion 
 Administration of IV methylprednisolone 125mg 
 Administration of IV diphenhydramine 50mg 
 Administration of IV ranitidine 50mg or IV famotidine 20mg 
 If there is increase in edema administer adrenaline 0.1% 0.3ml s.c 
 Icatibant selective bradykinin B2 receptor antagonist 30mg s.c in 
abdominal area 
 Supportive measures 
INTRACRANIAL BLEEDS
67
  
 Intracranial hemorrhage is the most feared complication of thrombolytic 
therapy. The hemorrhages are divided into  
 Hemorrhagic transformation - small petechiae without mass effect 
 Parenchymal hematoma – consisting of blood clot.  
They are also divided as 
 Asymptomatic or minor bleeds 
 Symptomatic or major bleeds(sICH) 
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Figure-12 minor bleed after thrombolysis. 
 Most of the sICH is caused by parenchymal bleed leading to mass effect 
and may also be life threatening. The risk factors for developing sICH are 
 Effect of drug IV rt-PA 
 Extent of hypoattenuation pretreatment CT 
 History of cardiac failure 
 Increasing age  
 Increased baseline blood pressure 
 Previous treatment with asprin. 
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MANAGEMENT OF INTRACRANIAL BLEED: 
 Stop alteplase infusion 
 CBC, PT (INR), aPTT, fibrinogen level, blood grouping and cross-match 
 Emergency NCCT 
 Cryoprecipitate (includes factor VIII): 10 U infused over 10–30 min.  
 Administer additional dose for fibrinogen level of <200 mg/dL 
 Tranexamic acid 1000 mg IV infused over 10 min  
 ε-aminocaproic acid(4–5 g over 1 h, followed by 1 g IV until bleeding is 
controlled) 
 Hematology and Neurosurgery consultations 
 Supportive therapy, including BP management, temperature, and glucose 
control 
ENDOVASCULAR INTERVENTIONS
70
 
 Mechanical Clot Disruption/Extraction(thrombectomy) 
 Intra-arterial Fibrinolysis 
 Acute angioplasty and stenting  
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MECHANICAL THROMBECTOMY 
 The patients who are eligible for mechanical thrombectomy are selected 
by the following criteria 
 Prestroke mRS score of 0 to 1 
 Occlusion of the internal carotid artery or MCA segment 1 (M1) but can 
also be used for other vessels also 
 Age ≥18 years 
 NIHSS score of ≥6 
 ASPECTS of ≥6  
 Treatment can be initiated within 6 hours of symptom onset. 
 The shorter the time window of thrombectomy better the results will be. 
 MERCI-Mechanical Embolus Remover in Cerebral Ischemia is the device 
approved for thrombectomy. 
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Figure – 13 MERCI Retriver  
INTRACRANIAL ACUTE ANGIOPLASTY AND STENTING 
 Urgent angioplasty with adjunctive stent placement is used to restore 
antegrade flow, with or without fibrinolysis or clot extraction. Retrievable stents 
are the newest approach to endovascular recanalization. These stent retrievers 
reperfuse tissue immediately and then used to engage and retrieve the clot. 
ANTI-PLATELET DRUGS
71,72,
 
 For those treated with IV alteplase, aspirin administration is generally 
delayed until 24 hours later. The use of glycoprotein IIb/IIIa receptor 
antagonists, like abciximab, in the treatment of AIS is potentially harmful and 
hence contraindicated. 
 In patients presenting with minor stroke, treatment for 21 days with dual 
antiplatelet therapy (aspirin and clopidogrel) begun within 24 hours can be 
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beneficial for early secondary stroke prevention for a period of up to 90 days 
from symptom onset. 
ANTICOAGULANTS
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 Use of anticoagulants in the treatment of AIS is found to have no benefit. 
In fact it causes more harm and so use of heparin or heparinoids for urgent 
management of AIS is contraindicated.  
 Use of factor Xa inhibitors are also not useful. When the patient is already 
on these drugs IV thrombolysis or other interventions are contraindicated. 
  Thrombin inhibitors like Agatroban and Dabigatron are also tried for 
treatment of AIS but they are of limited use and there is no sufficient supporting 
evidence till now. 
SURGICAL INTERVENTIONS IN AIS
67
 
 Cerebral and cerebellar edema is one of the important sequelae of AIS. 
 In patients with unilateral MCA infarctions who deteriorate 
neurologically within 48 hours despite medical therapy, decompressive  
craniectomy with dural expansion may be useful since it reduces mortality. 
Ventriculostomy is recommended in the treatment of obstructive hydrocephalus 
after a cerebellar infarct. Decompressive suboccipital craniectomy with dural 
expansion should be performed in patients with cerebellar infarction. 
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 Use of osmotic therapy like mannitol infusion in patients with clinical 
deterioration can be encouraged. Use of brief moderate hyperventilation is a 
treatment option for patients with acute severe neurological decline from brain 
swelling. 
OTHER EXPERIMENTAL THERAPIES 
 Volume Expansion, Vasodilators  
 Induced Hypertension 
 Albumin for Treatment of Acute Ischemic Stroke 73,74 
 Mechanical Flow Augmentation 
 Neuroprotective Agents 
 Hypothermia 
 Hyperbaric Oxygen 
 Near-Infrared Laser 75-78 Therapy 
 All the above therapeutic interventions are in experimental levels and are 
of no proven benefit. These are not recommended as per latest guidelines. 
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 SUPPORTIVE MEASURES AFTER THROMBOLYSIS AS IN-PATIENT 
IN HOSPITAL 
 All patients to be taken care in Neuro ICU for atleast 24 hours. 
 Blood pressure, euvolemic status, blood glucose levels and temperature 
are maintained as recommended. 
 Prevention of aspiration and use of dysphagia screening 
 Nutrition and oral hygiene is taken care of. 
 DVT prophylaxis in immobile patients 
 Screening for post stroke depression. 
 Routine antibiotic prophylaxis is not recommended 
 Skin care and prevention of bedsores. 
 Rehabilitation and physiotherapy. 
 Smoking cessation and risk factor modification. 
 Stroke education for patients and caregivers. 
FOLLOW UP 
 The outcome of patients undergoing acute thrombolysis is assessed after 3 
months. The real good outcome
79 
of the therapy lies in not in treating the patient 
acutely or administering the drug in time, it is the quality of life the patient 
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attains after the therapy. The real success of therapy is attaining fully 
independent and productive life. This is assessed by regular follow up of the 
patient after discharge. The reassessment of patient is done usually at the end of 
3 months. Many scales are available for assessment of disability and dependency 
of patient in the post stroke period. They are  
 Modified Rankin Score(mRS)80 
 Barthel index 
 Glascow outcome scale. 
 Of the above the most accepted scale is modified Rankin score. 
MODIFIED RANKIN SCORE
80
 
 The score was originally devised by Dr.John Rankin and then modified 
by Prof.C.Warlow. The modified version is now the widely accepted scale used 
all over the world for academic purposes the scale consists of score from 0-6. A 
score of 0-2 is considered a good outcome. It is the positive outcome of the 
therapy given. 
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Table - 15 
CLINICAL OUTCOME SCORE 
No symptoms 0 
No significant disabilities, despite symptoms, able to perform all 
usual duties and activities 
1 
Slight disability, unable to perform all previous activities, but 
able to look after own affairs without assistance 
2 
Moderate disability, requires some help, but able to walk without 
assistance 
3 
Moderately severe disability, unable to walk without assistance 
and unable to attend own bodily needs without assistance 
4 
Severe disability, bedridden, incontinent and requires constant 
nursing care and attention 
5 
Death  6 
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MATERIALS AND METHODS 
 This study was conducted at a tertiary care hospital during the period 
from March 2018 to August 2018, after getting ethics committee clearance. 
Type of Study: Prospective descriptive study. 
Study center: Tertiary care Centre in Chennai 
AIM OF THE STUDY 
 The aim of present study is to assess the clinical outcome and 
improvement in quality of life of patients undergoing intravenous thrombolysis 
for acute ischemic stroke in tertiary care center 
PRIMARY OBJECTIVES  
 To study the clinical profile of patients undergoing thrombolysis for acute 
stroke presenting within window period (4.5hrs). 
SECONDARY OBJECTIVE 
  To study the improvement in physical quality of life after intravenous 
thrombolytic therapy in acute ischemic stroke.  
STUDY BACKGROUND 
 Acute stroke is one of the major health problem causing mortality and 
long term morbidity and disability worldwide. 
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 Neural tissue is very sensitive to ischemic insult and causes permanent 
disability once the treatment is delayed. 
           Modern management of stroke includes rapid assessment, protocol wise 
approach, thrombolysis for acute ischemic stroke, early specialist management 
and appropriate  monitoring. 
 Thrombolysis is a key intervention for patients presenting early within 
window period of 4.5 hours. Long term outcome of the therapy is to improve 
physical quality of life and reduction of dependency on others. 
JUSTIFICATION OF STUDY 
 Positive outcome of the study encourages use of thrombolysis 
extensively, as an important modality of treatment of acute stroke in future 
INCLUSION CRITERIA 
 Age >18 years<80 years 
 Onset of symptoms to time of drug administration  <4.5hrs 
 Measurable neurological deficit defined as impairment of language, motor     
function, cognition and/gaze, vision or neglect 
 Score for stroke severity >4 on the NIHSS score 
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EXCLUSION CRITERIA 
1. Age >80 yrs 
2. Minor stroke(NIHSS<4 ) / major stroke(NIHSS>22) 
3.  Prior use of antiplatelet  / GI bleed in preceding 21 days 
4.  Stroke /TIA/Head injury in preceding 3months 
5. Myocardial infarction in preceding 3 months 
6.  Major surgeries in preceding 14 days 
7.  Radiologically demonstrable stroke with ASPECT score <6 
Sample size: 30 
PROCEDURE 
  The detailed history of the patients was recorded and patients underwent 
a detailed clinical examination. Patients were assessed according to NIHSS score 
at the time of admission. Early routine investigations including imaging with non 
–contrast CT scan were done. Patients were thrombolysed using intra venous 
Alteplase 0.9 mg/kg (10% of dose as bolus and 90% over hour).  After 
administration of intravenous thrombolytics, patients were observed in ICU. 
Reassessment of patient was done after 24 hours to look for primary outcome i.e 
decrease in NIHSS score by ≥4 indicating good prognosis in that patient. Repeat 
CT is done to rule out any bleeding complications. 
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  After stabilizing the patient they were started on routine stroke 
management with anti-platelets and rehabilitation therapy. Patients were 
discharged and routinely followed up. At the end of 3 months patients were 
assessed by using Modified Rankin Score. This scoring provides the clinical 
outcome and improvement in quality of life in post stroke period. 
INFORMED CONSENT  
 Consent form was written in both English and Tamil and consent 
obtained from all the participants, confidentiality is maintained. 
STATISTICAL ANALYSIS  
 The results are analyzed using IBM.SPSS statistical software. Continuous 
variables are expressed as mean standard deviation. Categorical variables are 
expressed as percentage. 
* Conflict of interest if any - Nil 
* Privacy/confidentiality of study subjects - Maintained 
* Sponsor details - Not Applicable 
* Compensation - Not Applicable 
* Insurance - Not Applicable 
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RESULTS AND STATISTICAL ANALYSIS 
AGE DISTRIBUTION 
 
 Among the sample studied the maximum age group falls in the range of 
51-60yrs of age with 43.3% of study population in this group. 
  Least common group is the age group under 40 yrs comprising 6.7% of 
the study population. 
  The mean age of presentation is 54.77. 
 Standard deviation is 8.869. 
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GENDER DISTRIBUTION  
 
 Among the study population male patients were 63% . 
 Female patients were 37%. 
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TIME OF PRESENTATION (WINDOW PERIOD) 
 
 The patients selected are those who presented within 4.5 hrs from the time 
of onset of symptoms 
 Among them 77% presentated within 3 hours. 
 Remaining 23% presented in the extented window period of 3-4.5 hours. 
 There is no significant differences in primary outcome in patients 
presented in 3-4.5 hrs. 
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DISTRIBUTION OF RISK FACTORS 
 
 The study population who had multiple risk factors are  57%.  
 23% had a single  risk factor. 
 20% had no asociated risk factors. 
   
20% 
23% 57% 
RISK FACTORS 
NIL SINGLE  RF MULTIPLE  RF
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BLOOD PRESSURE AT THE TIME OF ADMISSION 
 
 Among the sample population 90% of the patients presented in the range 
of BP <185/110 mmHg.  
 10% of them had high BP more than 185/110mmHg. 
 The mean systolic BP at presentation is 155 mmHg with standard 
deviation of 22.689 
 The mean diastolic BP at presentation is 91mmHg with standard 
deviation of 10.289 
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NEED FOR ANTI HYPERTENSIVE 
 
 83% of the study population does not need  an IV anti-hypertensive for  
control of blood pressure.  
 17% of them needed to be treated with IV anti-hypertensive, that is IV 
labetelol was given to reduce the BP before thrombolysis. 
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CAPILLARY BLOOD GLUCOSE AT THE TIME OF ADMISSION 
 
 37% of the patients were having a high blood glucose level( >200mg/dl) 
at the time of admission and needed immediate measures to reduce the 
blood pressure. 
  63% had normal CBG at the time of presentation. 
 The mean capillary blood glucose at presentation is 166 mg/dl 
 The standard deviation is 54.425. 
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NIHSS AT THE TIME OF ADMISSION 
 
 The NIHSS score at the time of admission in the range of 5-9  is 23%  
 The NIHSS at admission in the range of 10-22 is about 77%.  
 The mean score at presentation is 12.60  
 Standard deviation is 4.174. 
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NIHSS AFTER 24 HOURS OF ADMISSION 
 
 After 24 hrs of admission the NIHSS score in the range of 5-9 is 70% 
 The score in the range of 10-22 is 30% 
 The mean score is 7.83 
 The standard deviation is 5.299 
73 
CT SCAN TAKEN AT ADMISSION 
 16.7% presented with early CT changes. 
 83.3% presented with normal CT at the time of admission 
ASPECT SCORE 
 The maximum score is 10 
 The minimum score presented is 7 
 The mean ASPECT SCORE  is 9.60 
 The standard deviation is 0.932. 
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CT AFTER 24 HOURS 
 
 50% the study population had ischemic changes in the CT taken after 24 
hrs 
 43% had no significant change in CT that is the CT was normal. 
 7% had hemorrhage in the CT taken after 24 hrs. 
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PRIMARY OUTCOME: (REDUCTION IN NIHSS SCORE BY 4) 
 
 The primary outcome (i.e) reduction of NIHSS by 4 points from the 
initial score is present in 60%  of the study population. 
 Primary outcome is absent in 40% of the study population. 
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COMPLICATIONS 
 
 87% had no complication after the therapy. 
 6% had minor bleeding manifestations.  
 7% had skin rashes.  
 No one had major bleeding manifestations. 
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MODIFIED RANKIN SCORE 
 
 The 23.3%  of  study populaton had a score of 0. 
 30% had a score of  1. 
 23.3% had a score of 2 
 So the percentage of study population  who had a score of 0-2 is 76.6% 
 23 % had scores more than 2 
 The mean score is 1.70 
 The standard deviation is 1.557 
78 
DISCUSSION 
 The age group of presentation was analysed. The most common range of 
age of presentation was 51-60 years. And the least presenting group was age <40 
years. Thus the prevalance is maximum in theage group of51-60 years which is 
benefited by the thrombolytic therapy used for acute ischemic stroke. 
 The study done by Boehme AK, Siegler JE, Mullen MT, Albright KC, 
Lyerly MJ, Monlezun DJ, et al. shows the gender distribution as predominant in 
males. In our study also showed male predominance in the patients undergoing 
thrombolysis. Male comprises of 63% of patients undergoing thrombolysis. 
 According to ASA/AHA guidelines the window period for presentation of 
stroke patients is extended from 3hrs to 4.5 hrs. The patients in the group of time 
window 3-4.5 hrs also had positive primary outcome. There is no significant 
differences in primary outcome in patients presenting in<3 hrs and in the 
extended window period of 3-4.5 hrs. 
 Kim BJ, Park JM, Kang K, Lee SJ, Ko Y, Kim JG, et al. studied the 
prevalence of risk factors stated that the presence of multiple risk factors is more 
common in  patients suffering from acute ischemic stroke. About 57% of the 
study population had multiple risk factors like hypertension, diabetes, 
dyslipidemia, smoking, alcoholism and cardiac illness. 23% had single risk 
factor the most common being hypertension. 20% of the study population had no 
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pre-existing risk factors. This signifies that even in the absence of significant 
risk factors, acute ischemic stroke can occur. 
 90% of the study population presented with a BP <185/110 mmHg and 
10% with BP >185/110. The mean SBP is155mmHg and mean DBP is 91mmHg 
which correlates well with the  study done by Qureshi AI, Ezzeddine MA, Nasar 
A et al. 
 The need for IV anti hypertensive drugs before the administration of 
alteplase is about  17% which correlates with the data providedby the study of  
Rodríguez-García JL et al in which the need for anti-hypertensives is studied to 
be 18%. 
 Bruno A et al stated that the mean blood glucose at the time of 
presentation is about 170mg/dl and about 40% of the patients had high blood 
sugar levels at the time of presentation. In our study the mean blood sugar level 
is 166 mg/dl and 37% of patients needed correction of blood glucose levels 
before thrombolysis 
 Jagni SP et al in his study had maximum number of cases with NIHSS at 
the time of admision in the range of 10-22 (80%) and the mean NIHSS at 
admission was 13.5. In our study 77% of them are in the range of score 10-
22,with mean NIHSS  was 12.60 and standard deviation is 4.174. This value 
closely correlates with above study hence statisticaly significant. 
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 The NIHSS  after 24 hours  in the range of 5-9 was about 70% and score 
of 10-22 is 30%. The mean value is 7.38 with standard deviation 5.29. There is 
significant reduction in the score and the shift to the range from 10-22 to 5-9. 
There is a significant reduction in mean score at admission from 12.60 to 5.29. 
The difference is 7.31.  
 Of the CT brain  taken at the time of admission 87.3% were normal. 
16.7% had early CT changes. The ASPECT score of those with early CT 
changes were maximum of 10 and minimum of 7. The mean score is 9.60 with 
standard deviation of 0.9. This data correlates well with the study done by 
Pexman JH, Barber PA et al 
 The CT brain taken after 24 hours had ishemic changes in about 50% of 
cases and 7% had hemorrhagic changes. 43% showed no significant changes. 
This correlates closely with the data by study of Latchaw RE et al which  had 56 
% of ischemic changes and  6  % had hemorragic changes. 
 The primary outcome of the study is the reduction of NIHSS by ≥4  by 24 
hours from the time of admission. Jagni et al showed that 57.7% showed 
significant reduction of NIHSS by 4. Our study showed 60% of cases with 
positive primary outcome which closely correlates with the above study which is 
statisticaly significant. 
 The complications after the thrombolysis are mostly nil (87%). Only a 
small proportion suffered minor bleeding manifestations(7%) and skin 
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manifestations by(6%). This correlates with the data from the study by 
Sandercock et al in which the occurrence of hemorrhage is 7.7%. There were no 
patients in our study who had life threatening major bleeding manifestations or 
other major complications. 
  Modified Rankin Score is done to assess the disability  and physical 
quality of life at the end of 3 months. The score of 0-2 is considered as the good 
outcome which provides independent life to the patients suffering. The better the 
mRS score  the quality of life after stroke will be better. The full outcome of 
therapy is the significant reduction in mRS score at the end of 3 months which is 
considered as secondary outcome of this study. The over all score of mRS in the 
range of 0-2 in our study is 76.6%. This correlates well with the data by Jagni et 
al who stated that 76.9% had favourable outcome at the end of 3 months. This 
value is statisticaly significant and many studies show similar outcome. 
INFERENCE 
 This  study gives a statisticaly significant result as the primary outcome 
being positive. There is substantial and desirable decrease in NIHSS score 4 in 
about 60% and 77% showed improvement in their quality of life at the end of 3 
months. This signifies that the use of intravenous thrombolysis in patients 
presenting with acute ischemic stroke within the window period of 4.5 hours is 
beneficial for the patient, and there is a great improvement in quality of life 
which is assessed after 3 months. Complications of this therapy are also limited 
and occurrence of major life threatening complications like intracranial bleed is 
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very less. As per the recent 2018 ASA/AHA guidelines the patients are to be 
carefully selected and prompt treatment with intravenous thrombolysis is of 
great use to the patient in preventing permanent disability affecting the quality of 
life of the patient in the forthcoming years. This ultimately reduce the burden of 
the society in the form of rehablitation of lives of people and helps them to lead 
an independent and dignified life. 
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CONCLUSIONS 
 The most common age group affected is 51-60 yrs with 43.3% and least 
affected age group is <40rs with 6.7%. 
 Males are predominantly affected 63%. 
 77% of them presented within the window period of <3hrs and 23%in 3-
4.5 hrs. 
 Presence of multiple  risk factors contribute to occurence of acute 
ischemic stroke ( 57%). 
 10% of patients presented with high BP of >185/110mmHg at the time of 
admission 
 17% of them needed IV anti-hypertensive drugs to reduce the initial BP 
 37% of the study population had high blood sugar at the time of 
admission. 
 The mean blood sugar value at admission is 166mg/dl. 
 The mean NIHSS at the time of admission is 12.60 
 The mean NIHSS after 24 hours is 7.83  
 About 83% had a normal CT  and 17% early CT changes at the time of 
admission 
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 The mean ASPECT SCORE  is 9.60 
 50% had ischemic changes   and 7% had hemorrhagic  manifestations in 
CT taken 24 hours later. 
 Primary outcome(reduction in NIHSS by 4 points) was present in 60%. 
 87% had no significant complications, only 6 % had minor bleeding 
manifestations  and 7% had skin manifestations. 
 The secondary outcome( i.e) mRS of 0-2 at the end of 3 months 76% .                                                      
 
 
 
 
 
 
 
 
 
 
ABBREVATIONS 
AIS   - Acute Ischemic Stroke 
aPTT   - Activated Partial Thromboplastin Time 
ASPECTS  - Alberta Stroke Programme Early CT score 
ASRH  - Acute Stroke Ready Hospital 
BP   - Blood Pressure 
CBC   - Complete Blood Count 
CMB   - Cerebral Micro Bleeds 
CNS   - Central Nervous System 
CSC - Comprehensive Stroke Center 
CT - Computed Tomography 
DVT -  Deep Vein Thrombosis 
ECG - Electrocardiogram  
ECT - Ecrine Clotting Time 
ESRD - End Stage Renal Disease 
FAST - Face,Arm,Speeh,Time 
HD - Hemodialysis 
HMCA - Hyperdense Middle Cerebral Artery 
ICU - Intensive Care Unit 
INR - International Normalised Ratio 
IV - Intravenous 
LMWH - Low Molecular Weight Heparin 
MCA - Middle Cerebral Artery 
MI - Myocardial Infarction 
MRA - Magnetic Resonance angiography  
MRI - Magnetic Resonance Imaging  
MRS - Modified Rankin Score 
MTICI -  Modified Treatment in Cerebral Ischemia   
NCCT - Non Contrast Computed Tomography 
NIHSS - National Institute of Health Stroke Scale 
PSC - Primary Stroke Center 
PT - Prothrombin Time 
rt-PA - Recombinant  Tissue Plasminogen Activator 
sICH - Symptomatic Intracranial Hemorrhage 
TT - thrombin time 
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A  STUDY OF CLINICAL PROFILE OF PATIENTS 
UNDERGOING STROKE THROMBOLYSIS IN A TERTIARY 
CARE HOSPITAL   
PROFORMA  
NAME :   AGE:     SEX: 
 
ADDRESS:    CONTACT NO: 
 
 
COMPLAINTS: 
 
 
HISTORY 
 
       TIME SINCE ONSET OF WEAKNESS 
 
 
        ASSOCIATED FEATURES AT THE TIME OF ONSET   
        
         SEIZURES 
            HEADACHE 
            TRAUMA 
             
HISTROY OF CO-MORBID ILLNESS AND PAST HISTROY 
              T2DM:              
              SHT:        
              CAD / MI IN LAST 3 MONTHS                  
              STROKE / TIA / ICH IN 3 MONTHS 
              RECENT MAJOR SURGERIES 
              RECENT ACTIVE BLEEDING MANIFESTATIONS/ ON    
     ANTICOAGULANTS 
              PREGNANCY 
              PSYCHIATRIC ILLNESS 
PERSONAL HISTROY 
              DRUGS/  TOXINS/ SUBSTANCE ABUSE 
 
CLINICAL EXAMINATION: 
 
GENERAL EXAMINATION:  
 
SYSTEMIC EXAMINATION: 
 
CARDIOVASCULAR SYSTEM: 
 
RESPIRATORY SYSTEM: 
 
GASTRO-INTESTINAL SYSTEM : 
 
CENTRAL NERVOUS SYSTEM :  
 
NIHSS SCORE AT THE TIME OF ADMISSION: 
 
 
INVESTIGATIONS: 
      ROUTINE INVESTIGATIONS: 
                      CBC:                              RFT:                         RBS:                 
         
       NON CONTRAST CT BRAIN:  
                          AT ADMISSION  
                          AFTER 24 HOURS 
       MRI BRAIN 
        
 
TIME OF STARTING TROMBOLYSIS: 
 
 
ASSESSMENT OF PATIENT WITH NIHSS SCORE AFTER 24 HOURS 
 
 
COMPLICATIONS : 
COMPLICATIONS YES  NO 
ALLERGIC REACTIONS   
MINOR BLEEDING 
MANIFESTATIONS 
  
MAJOR BLEEDING 
MANIFESTATIONS 
  
OTHERS 
 
  
DEATH   
 
ASSESSMENT USING MODIFIED RANKIN SCORE AFTER 3 MONTHS: 
       
CLINICAL OUTCOME SCORE 
No symptoms 0 
No significant disabilities, despite symptoms, able to perform all 
usual duties and activities 
1 
Slight disability,unable to perform all previous activities, but able 
to look afterown affairs without assistance 
2 
Moderate disability,requires some help,but able to walk without 
assistance 
3 
Moderately severe disability,unable to walk without assistance 
and unable to attend own bodily needs without assistance 
4 
Severe disability,bedridden,incontinent and requires constant 
nursingcare and attention 
5 
Death  6 
PATIENT INFORMATION SHEET 
A  STUDY OF CLINICAL PROFILE OF PATIENTS 
UNDERGOING STROKE THROMBOLYSIS IN A TERTIARY 
CARE HOSPITAL   
 I ,Dr.M.Yamini, post graduate Deparment of General Medicine 
,Government Stanley Medical College is going to undertake the study on the 
above mentioned topic 
 The purpose of this study is to assess the clinical outcome of patients 
undergoing stroke thrombolysis in our department 
 If you are willing to participate in this study you will be asked  some 
questions regarding your preference of health facilities during illness and its 
reasons and questions regarding financial dependency, self reported chronic 
illness, satisfaction with health services etc.,  
 Though you may not benefit directly from the study, it is possible that the 
findings of the study based on your response may be of great help in planning 
strategies for protecting you and other people in future. 
 I assure that all the information provided by you will be kept highly 
confidential and privacy is assured. Your identity won’t be revealed to anyone. 
The study may be published in scientific journal, but your identity will not be 
revealed. 
 Your participation in this study is voluntary and you can withdraw from 
this at any point of time 
                                                                      
      Signature/ left thumb impression of the participant                                             
 
INFORMED CONSENT  
A  STUDY OF CLINICAL PROFILE OF PATIENTS 
UNDERGOING STROKE THROMBOLYSIS IN A TERTIARY 
CARE HOSPITAL   
 The content of the information sheet dated __________ that was provided 
have been read carefully by me/explained in detail to me, in a language that I 
comprehend and fully understood the contents.  
 I confirm that I have had the opportunity to ask questions. 
 The nature and purpose of the study and its potential risks/benefits and 
expected duration of the study and other relevant details of the study have been 
explained to me in detail.  
 I understand that my participant is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal right being affected.  
 I agree to take part in the above study 
 _______________________________ 
 (Signature/Left thumb impression) 
 Name of the Participant: _________________________ 
 Son/Daughter/Spouse of  _________________________ 
 Complete postal address: _________________________ 
 This is to certify that the above consent has been obtained in my presence. 
 ______________________________                                                      
Date: 
Signature of the principal investigator 
Place: 
 
1) Witness – 1               2) Witness – 2 
 
Signature:        Signature: 
Name:        Name:                                                                                  
Address:       Address 
GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
A  STUDY OF CLINICAL PROFILE OF PATIENTS UNDERGOING 
STROKE THROMBOLYSIS IN A TERTIARY CARE HOSPITAL   
Place of study:  Govt. Stanley medical college, Chennai 
 
 I ……………………………………………. have been informed about 
the details of the study in my own language.I have completely understood the 
details of the study. I am aware of the possible risks and benefits, while taking 
part in the study.I agree to collect samples of blood/saliva/urine/tissue if study 
needs.I understand that I can withdraw from the study at any point of time and 
even then, I can receive the medical treatment as usual. I understand that I will 
not get any money for taking part in the study. 
 I will not object if the results of this study are getting published in any 
medical journal, provided my personal identity is not revealed. 
 I know what I am supposed to do by taking part in this study and I assure 
that I would extend my full cooperation for this study.    
 
Volunteer:       Witness: 
Name and address      Name and address  
Signature/thumb impression:   Signature/thumb impression 
Date:       Date: 
  
Investigator Signature and date                        
GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
A  STUDY OF CLINICAL PROFILE OF PATIENTS 
UNDERGOING STROKE THROMBOLYSIS IN A TERTIARY 
CARE HOSPITAL   
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MASTER CHART 
S.NO AGE SEX 
WINDOW 
PERIOD 
RISK 
FACTOR 
BP 
ANTI -
HT 
NIHSS AT 
ADM 
NIHSS AT 
24HRS 
CBG 
CT -
ADM 
ASPEC
T 
CT-24HRS COMPLIC 
PRIMARY 
OUTCOME 
MRS 
1 42 M A H/D/S 150/90 N 12 6 210 N 10 N N P 1 
2 70 F A H/D 160/90 N 10 6 200 N 10 N N P 2 
3 56 M A H 
200/10
0 
Y 10 5 110 N 10 I N P 2 
4 53 M B N 
200/11
0 
Y 7 6 135 E 8 I N A 2 
5 50 F A D 159/90 N 6 4 233 N 10 I N A 1 
6 50 M B H/S 140/90 N 6 0 126 N 10 N N P 0 
7 56 M A H/S/A 150/90 N 12 15 100 E 7 I N A 4 
8 38 M B S/A 130/80 N 8 4 95 N 10 H MNB P 1 
9 48 F A H/D/C/L 140/90 N 8 0 200 N 10 N N P 0 
10 65 M A H/T 150/90 N 12 0 158 N 10 I N P 0 
11 41 M A S/D/C/A 160/90 N 16 7 203 N 10 I N P 1 
12 50 F A H/D 160/90 N 10 7 202 N 10 I N A 1 
13 65 M A H/S 100/60 N 14 17 137 N 10 I N A 6 
14 56 F A N 
190/11
0 
Y 17 4 236 N 10 I N P 0 
15 37 M A S/A 140/80 N 15 10 142 N 10 H MNB P 2 
16 58 F A N 130/80 N 20 18 103 N 10 N N A 4 
17 60 M B D 150/90 N 10 8 215 N 10 I N A 0 
18 56 M A S/A 140/90 N 16 6 99 N 10 N N P 0 
19 65 M A S 
190/10
0 
Y 15 7 136 N 10 N N P 1 
20 60 F B D/H 160/90 N 16 15 298 E 7 I N A 5 
21 58 F A H 
170/10
0 
N 10 4 155 E 8 I N P 2 
22 43 M A D/H 150/90 N 20 18 236 N 10 N N A 3 
23 49 M A H/F 
160/10
0 
N 9 4 170 N 10 N N P 1 
24 65 F A N 150/90 N 8 3 109 N 10 N N P 1 
25 50 M B D 160/80 N 17 15 210 E 8 I N A 3 
26 70 M A H 
190/11
0 
Y 20 8 105 N 10 N N P 0 
27 60 F B N 170/90 N 16 13 128 N 10 I SR A 3 
28 59 M A D/A/S 130/80 N 10 6 214 N 10 I N P 2 
29 58 M A N 130/90 N 13 6 111 N 10 N N P 1 
30 55 F A H/D/O 
160/10
0 
N 15 13 222 N 10 N SR A 2 
                
 WINDOW PERIOD 
 
RISK FACTOR 
  
NEED FOR ANTI HYPERTENSIVE 
CT-AT 
ADMISSION 
    
A- <3hrs 
  
H- HYPERTENSION 
  
Y- YES 
  
N- NORMAL 
    
B- 3-4.5hrs 
 
D- DIABETES MELLITUS 
 
N- NO 
  
E- EARLY CT CHANGES 
   
   
L-DYSLIPIDEMIA 
           
   
S- SMOKER 
           
   
A- ALCOHOLIC 
  
CT-24HRS 
 
COMPLICATION 
  
PRIMARY OUTCOME 
 
   
C- CARDIAC DISEASE 
   
N- NIL 
  
NIHSS REDUCED BY 4 
 
   
O-OBESITY 
  
N- NORMAL MNB- MINOR BLEED 
 
P- PRESENT 
  
   
T- H/O TIA 
  
I- INFARCT MJB-MAJOR BLEED 
 
A- ABSENT 
  
   
F- FAMILY H/O 
  
H- HEMORRAGE SR-SKIN RASH 
      
   
N- NIL RISK FACTOR 
   
A- 
ANAPHYLAXIS 
      
               
      
ASPECT SCORE 
 
CBG 
  
BP 
  MRS-Modified Rankin 
score 
   
10- NORMAL 
 
<200- NORMAL 
 
>185/110- NEED ANTI-
HYPERTENSIVE 
0- NO SYMPTOMS 
    
6-10- EARLY CT CHANGES 
 
> 200- HIGH 
    1- ABLE TO PERFORM ALL DUTIES AND 
ACTIVITIES 
  
<6 - FORMED INFARCT 
       2-SLIGHT 
DISABILITY 
             3- MODERATE 
DISABILITY 
            
4- MODERATELY SEVERE DISABILITY 
           
 5-SEVERE DISABILITY 
            
6- DEATH 
              
                
